Inspiring plenary by Salim & Quarraisha Abdool Karim #ICTMC2022

Lucinda Billingham presenting BOP methods in umbrella and basket studies in rare cancer treatments. Data sharing with DRUP intended. @ictmc2022

Lovely work by Karen Bracken NHMRC CTC

Which factors affect participant choice of electronic vs paper pt-reported outcomes & how did the pandemic further affect this choice? Really interesting results from Kirsteen Goodman @NMAHPRu #ICTMC2022

Another beautiful initiative from HRB-TMRN : The People’s Trial (trialsjournal.biomedcentral.com/articles/10.11…) A trial completely designed by the public #ICTMC2022

Thought provoking talk about involving the public in outcomes and the quantitative elements of a clinical trial. Beatriz Goulão @ictmc2022 lots of messages for NHMRC CTC

Brilliant last keynote speaker Max Parmar. Great practical advice on designing & running MAMS platform trials. Key advice for #trialmanagers: * keep calm * clear roles & responsibilities are essential * exceptionally clear processes needed #ICTMC2022 UKTMN

Great question re. advice for trial management teams working on platform #clinicaltrials - good opportunity to plug @mrcctu trio of papers on implementing platform protocols mrcctu.ucl.ac.uk/news/news-stor… #ICTMC2022

Superb #ICTMC2022 keynote from Max Parmar on #MAMS trials. Excellent insights…incl *Choose interventions as different as possible *IDMC key - use experienced members *Only plan large adaptations *Plan for how the control arm might need to change *Build it & trials will come!

I promised to share some slides from my #ICTMC2022 presentation on removing barriers to trial participation for LGBTQIA+ people. A project that I am passionate about! 1/

This slide gives trial teams a 'how to' on making your trials more inclusive. Karen Bracken did a great job of talking us through her work at #ICTMC2022 on how to improve trials for LGBTQIA+ people 🏳️‍🌈🏳️‍🌈🏳️‍🌈

A good first keynote day 2 on the EVBRES - COST Action #EBRconf2022 .Interesting presentation by Arianne Verhagen on redundant clinical trials. Important subject, how to decide when no more studies are needed.

We're thrilled to see national media coverage of the MoST study. Co-ordinated by NHMRC CTC, MoST is the leading Australian program delivering molecular screening and trials matching to advanced cancer patients. Watch via A Current Affair: 9now.nine.com.au/a-current-affa… #Oncology

Omico is proud to be a part of this study. ASPiRATION is screening tumour tissue from people anywhere in Australia with newly diagnosed metastatic lung cancer using comprehensive genomic profiling (CGP), providing patients with opportunities to receive novel targeted treatments.

Working together with other UK trial units, we have looked at multiple platform trials and drawn together 📝 recommendations on how to run them

#cholangiocarcinoma: better real-world outcomes are seen in patients who received genomic matched drugs in the MoST study. Time to treat CCa like lung ca. Trials/drug access must improve. #AGITG22 Subo #Precision Omico Australia NHMRC CTC

The World Indigenous Cancer Conference has started with energy, optimism and ceremony. I am privileged to be here and I am looking forward to learning from this gathering. #WICC 2024 Omico Australia